Equities researchers at Barclays assumed coverage on shares of ImmunoGen (NASDAQ:IMGN – Get Rating) in a research report issued on Friday, The Fly reports. The firm set an “overweight” rating on the biotechnology company’s stock.
Separately, StockNews.com lowered ImmunoGen from a “hold” rating to a “sell” rating in a research report on Monday, August 1st. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, ImmunoGen presently has an average rating of “Hold” and a consensus price target of $10.25.
ImmunoGen Stock Up 1.9 %
NASDAQ:IMGN opened at $5.46 on Friday. The business’s 50-day moving average price is $5.37 and its two-hundred day moving average price is $4.84. ImmunoGen has a twelve month low of $3.10 and a twelve month high of $7.77. The stock has a market cap of $1.21 billion, a P/E ratio of -7.91 and a beta of 0.90.
Hedge Funds Weigh In On ImmunoGen
Institutional investors and hedge funds have recently bought and sold shares of the stock. Xponance Inc. bought a new position in ImmunoGen during the 1st quarter worth approximately $49,000. Nisa Investment Advisors LLC lifted its stake in shares of ImmunoGen by 116.9% in the 2nd quarter. Nisa Investment Advisors LLC now owns 10,390 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 5,600 shares during the period. HighTower Advisors LLC purchased a new position in shares of ImmunoGen in the 4th quarter valued at approximately $77,000. Bank of Montreal Can purchased a new position in shares of ImmunoGen in the 2nd quarter valued at approximately $47,000. Finally, NewEdge Wealth LLC purchased a new position in shares of ImmunoGen in the 2nd quarter valued at approximately $52,000. 95.58% of the stock is currently owned by institutional investors.
ImmunoGen, Inc, a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm.
- Get a free copy of the StockNews.com research report on ImmunoGen (IMGN)
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
- When Will the Hangover Finally Be Over for Seagate Technology?
- Are These Green Energy Companies Right For Your Portfolio?
- Does Enphase Energy Have the Juice to Keep Powering Higher?
- The One Hydrogen Fuel Cell Stock To Rule Them All
Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.